Among these, NME2 was selected for further functional validation due to its significant overexpression in ccRCC, its strong prognostic association, and most importantly, the compelling biological plausibility that its known role in nucleotide metabolism could directly underpin the enhanced oxidative phosphorylation phenotype observed in high-SRSM tumors. Here, NME2 is linked to nonpapillary renal cell carcinoma.